自体造血干细胞移植与新药联合治疗多发性骨髓瘤  

Autologous Hematopoietic Stem Cell Transplantation Combined with Novel Drugs for the Treatment of Multiple Myeloma

作　　者：万茜茜 余涛[1] 余甜 

机构地区：[1]三峡大学附属仁和医院血液肿瘤科,湖北 宜昌

出　　处：《临床医学进展》2025年第2期1734-1743,共10页Advances in Clinical Medicine

摘　　要：多发性骨髓瘤(Multiple Myeloma, MM)是一种不可治愈血液系统恶性肿瘤,由浆细胞单克隆性异常增生引起具有广泛的遗传和临床特征。好发于中老年人,占所有血液系统癌症的10%。虽然多发性骨髓瘤仍是无法治愈的疾病,但是随着21世纪引入新型药物(如蛋白酶体抑制剂、免疫调节剂、单克隆抗体等)的应用与自体造血干细胞移植联合治疗,大大提高了多发性骨髓瘤患者总生存率(Overall Response, OS),尤其是在年轻患者中有显著改善。在此篇综述中,我们将从自体造血干细胞移植的适应症和必要性、诱导疗法、干细胞动员与预处理方案、巩固治疗、维持治疗,5个方面来总结关于自体造血干细胞移植在多发性骨髓瘤治疗中的进展以及展望未来,在充分的研究数据支持下,通过个性化的精确治疗来提高患者生存率。Multiple Myeloma (MM) is an incurable hematologic malignancy caused by an abnormal monoclonal proliferation of plasma cells with a wide range of genetic and clinical features. It is prevalent in middle-aged and elderly people and accounts for 10% of all hematologic cancers. Although multiple myeloma remains incurable, the introduction of novel drugs (e.g., proteasome inhibitors, immunomodulators, monoclonal antibodies, etc.) in the 21st century in combination with autologous hematopoietic stem cell transplantation has greatly improved the overall survival (Overall Response, OS) of patients with multiple myeloma, especially in younger patients. In this review, we will summarize the progress of autologous HSCT in the treatment of multiple myeloma from five aspects: indications and necessity of autologous HSCT, induction therapy, stem cell mobilization and pretreatment regimen, consolidation therapy, and maintenance therapy, as well as look forward to the future, and to improve the survival rate of patients through personalized and precise treatment supported by sufficient research data.

关 键 词：多发性骨髓瘤 诱导疗法 自体造血干细胞移植 造血干细胞动员 巩固治疗 维持治疗 

分 类 号：R73[医药卫生—肿瘤]